With pro-cannabis legislation gaining steam across the United States, investors across the globe have been seeking opportunities to put their hands in the figurative cannabis cookie jar. More than half of the states have legalized medical marijuana, and an increasing number of states have already legalized recreational-use marijuana. There is no single investment that is perfect for all investors, but the cannabis industry has a wide variety of investment opportunities in this day and age, and that means there’s an investment opportunity for nearly every type of investor.
Earth Science Tech, Inc. (OTCMKTS:ETST) is trading at $0.3909 per share, and with just over 4 million shares in its float, the stock can move very quickly and provide investors with high volatility under the right conditions. The company specializes in producing different flavors of its high grade hemp CBD oil, which can be used to treat anything from skin conditions and pain to neurological and psychological symptoms. Perhaps the company’s largest focus as of late has been treating 9/11 first responders and military veterans who suffer from post-traumatic stress disorder (PTSD). The company has taken a firm hold on the medical side of the marijuana market, and they have been acquiring other biotech companies in hopes to extend their distribution network and product development capacity.
For more traditional blue chip investors, GW Pharmaceuticals (NASDAQ:GWPH) has been an interesting company to invest in. The company is widely known for achieving the first mass-market/government approval for a cannabinoid prescription medicine, and as such, they have quickly grown to be among the largest cannabis-based companies in the world. The company is based in the UK, and as such, it is only tradeable on the Nasdaq via an ADR. The GWPH ADR is currently trading at $117.08 per share, and has seen higher than average volatility as American markets open up more to them and the industry as a whole is seeing much better consumer sentiment. The company has taken a focus in treating epilepsy, multiple sclerosis spasticity, and rare diseases with its flagship products: Epidiolex® and Sativex®.
For investors seeking an in-between company, Axim Biotechnologies, Inc. (OTCMKTS:AXIM) has been quite appealing. Trading at $8.99 per share, the company has seen tremendous growth over the past couple of months, when shares were trading as low as $0.25 per share. Investor excitement picked up surrounding AXIM after a series of news releases that the company had begun PK/PD studies on its CanChew Plus CBD gum, which aims to reduce suffering in IBS patients. The company has received a great deal of attention and positive news for its CanChew Plus CBD gum, including being granted a U.S. Patent and approval from a medical ethical committee to begin trials. The company is also actively seeking out more patents for IP such as its proprietary method to extract high-purity THC.
The potential in the cannabis market is exceptional right now, and companies in the industry are seeing a great deal of investor activity. Forbes recently stated that the CBD market could grow over 700% by 2020, and those are no numbers to scoff at. These three companies are positioning themselves to profit from the powerful wave of CBD acceptance and market growth. Keep an eye on ETST, GWPH, and AXIM in 2017.